Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 16, 2025

Dose Reducing and Sequencing Therapies in Desmoid Tumors

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Mrinal Gounder, MD, Gina D'Amato, MD

Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.

Episodes in this series

EP. 1 Key Background Information on Desmoid Tumors

EP. 1 Key Background Information on Desmoid Tumors

EP. 2 Exploring the Heterogeneous Nature of Desmoid Tumors

EP. 2 Exploring the Heterogeneous Nature of Desmoid Tumors

EP. 3 The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors

EP. 3 The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors

EP. 4 The Burden and Unmet Needs Associated with Desmoid Tumors

EP. 4 The Burden and Unmet Needs Associated with Desmoid Tumors

EP. 5 When to Observe Desmoid Tumors

EP. 5 When to Observe Desmoid Tumors

EP. 6 Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors

EP. 6 Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors

EP. 7 Novel Pharmacotherapies and NCCN Guideline Recommendations

EP. 7 Novel Pharmacotherapies and NCCN Guideline Recommendations

EP. 8 Examining a Novel FDA-approved Therapy in Desmoid Tumors

EP. 8 Examining a Novel FDA-approved Therapy in Desmoid Tumors

EP. 9 Dose Reducing and Sequencing Therapies in Desmoid Tumors

EP. 9 Dose Reducing and Sequencing Therapies in Desmoid Tumors

EP. 10 Insurance Coverage and Patient Education

EP. 10 Insurance Coverage and Patient Education

EP. 11 Additional Clinical Considerations for Desmoid Tumors

EP. 11 Additional Clinical Considerations for Desmoid Tumors

EP. 12 Optimizing Patient Care and the Potential of Artificial Intelligence

EP. 12 Optimizing Patient Care and the Potential of Artificial Intelligence

EP. 13 Unmet Needs and the Future of Desmoid Tumor Management

EP. 13 Unmet Needs and the Future of Desmoid Tumor Management

Panelists discuss the questions below in this video.

When is it appropriate to dose reduce with nirogacestat and how can this ensure the desired clinical outcomes are met?
How are you sequencing therapies in your institution?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Kevin Kaiserman, MD

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

ByGiuliana Grossi,Kevin Kaiserman, MD

June 5th 2026

Rising piles of coins indicating cost savings | Image credit: THAWEERAT - stock.adobe.com

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

ByLaura Joszt, MA

June 5th 2026

Noah Greenspan, DPT

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT

BySabrina McCrear,Noah Greenspan, DPT, PT, CCS, EMT-B

June 5th 2026

Doctor writes a script for asthma. | Image credit: @Goffkein - stock.adobe.com

SUNRISE Trial: Tezepelumab Reduces Steroid Use in Severe Asthma

BySabrina McCrear

June 5th 2026

tryptophan and nuts | Image credit: Danijela - stock.adobe.com

Disrupted Tryptophan Metabolism Linked to Psoriasis Severity, Multiple Comorbidities

BySkylar Jeremias

June 5th 2026

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

Plastic in Personal Care Products Tied to Skin Disease and Environmental Pollution, Review Finds

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD